News & Analysis on Clinical Trial Services & Contract Research And Development
AstraZeneca's troubles continued to add up after the company announced the application withdrawal of Iressa after it failed to show any significant survival benefit for patients with non-small cell lung cancer. The move places question marks over...
RNA interference (RNAi) technology took a major leap forward after Sirna Therapeutics initiated the first program that uses RNAi to treat asthma, a condition that costs an estimated $13 billion (€9.8 billion) in healthcare costs in the US.
In response to accusations of a cover up over negative data and placing patient safety at risk, pharmaceutical companies worldwide have agreed to reveal the results of clinical trial drug data.
The need for an effective HIV drug became apparent as the US Food and Drug Administration (FDA) granted Fast Track designation to the first in a new class of HIV drugs called Maturation Inhibitors.
Researchers have identified and tested an anti-sense oligonucleotide sequence that will kill strains of Methicillin Resistant (MRSA) and Vancomycin-resistant (VRSA) Staphylococcus aureus, which continue to cause a serious public health problem.
NextGen Sciences has licensed a new technology for protein expression from Oxford Brookes University that reduces expression timelines for proteins in insect cells by up to 10 days.